EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

The impact of remdesivir on SARS-CoV-2 evolution in vivo

Ted Ling-Hu, Lacy M Simons, Estefany Rios-Guzman, Alexandre Machado Carvalho, Maria Francesca R Agnes, Arghavan Alisoltanidehkordi, Egon A Ozer, Ramon Lorenzo-Redondo, Judd F Hultquist

JCI Insight · 24.02.2025 · 10 (4)

DOI: 10.1172/jci.insight.182376 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JCI Insight, online erschienen am 21.01.2025. Verfasst von Ted Ling-Hu und 8 weiteren Autor:innen. Beteiligte Einrichtung: Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA. Hauptthemen laut MEDLINE: Adenosine Monophosphate, Alanine, SARS-CoV-2, Antiviral Agents. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 77 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH HHS, NIAID NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The impact of remdesivir on SARS-CoV-2 diversity and evolution in vivo has remained unclear. In this single-center, retrospective cohort study, we assessed SARS-CoV-2 diversification and diversity over time in a cohort of hospitalized patients who did or did not receive remdesivir. Whole-genome sequencing was performed on 98 paired specimens collected from 49 patients before and after remdesivir administration. The genetic divergence between paired specimens was not significantly different in this cohort compared with that in a control group of patients who did not receive the drug. However, when we focused on minority variants, several positions showed preferential diversification after remdesivir treatment, some of which were associated with specific variants of concern. Most notably, remdesivir administration resulted in strong selection for a nonsynonymous mutation in nsp12, G671S, previously associated with enhanced viral fitness. This same mutation was found to be enriched in a second cohort of 143 inpatients with specimens collected after remdesivir administration compared with controls. Only one other mutation previously implicated in remdesivir resistance (nsp12:V792I) was found to be preferentially selected for after remdesivir administration. These data suggest that SARS-CoV-2 variants with enhanced replicative fitness may be selected for in the presence of antiviral therapy as an indirect means to overcome this selective pressure.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenosine MonophosphateAlanineSARS-CoV-2Antiviral AgentsCOVID-19 Drug TreatmentCOVID-19HumansRetrospective StudiesMaleFemaleMiddle AgedMutationEvolution, MolecularDrug Resistance, ViralAgedWhole Genome SequencingAdultViral Nonstructural ProteinsCoronavirus RNA-Dependent RNA Polymerase

Stichwörter der Autor:innen

COVID-19Drug therapyTherapeutics

Substanzen

remdesivirAdenosine MonophosphateAlanineAntiviral AgentsNSP12 protein, SARS-CoV-2Viral Nonstructural ProteinsCoronavirus RNA-Dependent RNA Polymerase

Autor:innen und Institutionen

  • Division of Infectious Diseases, Northwestern University Feinberg School of Medicine, Chicago, Illinois, USA.
  • Center for Pathogen Genomics and Microbial Evolution, Northwestern University Havey Institute for Global Health, Chicago, Illinois, USA.

Förderung

  • NIH HHS
  • NIAID NIH HHS
  • NCATS NIH HHS
  • NCI NIH HHS
  • Quantitative Biosciences Institute Coronavirus Research Group (QCRG) Antiviral Drug Discovery (AViDD) center
  • COVID-19 Supplemental Research awards from the National Institutes of Health’s (NIH’s) National Center for Advancing Translational Sciences
  • Northwestern University Cancer Center
  • NIH-supported Third Coast CFAR

Zitieren

APA

Ling-Hu, T., Simons, L. M., Rios-Guzman, E., Carvalho, A. M., Agnes, M. F. R., Alisoltanidehkordi, A., Ozer, E. A., Lorenzo-Redondo, R., & Hultquist, J. F. (2025). The impact of remdesivir on SARS-CoV-2 evolution in vivo. JCI Insight, 10(4). https://doi.org/10.1172/jci.insight.182376

Vancouver

Ling-Hu T, Simons LM, Rios-Guzman E, Carvalho AM, Agnes MFR, Alisoltanidehkordi A, et al. The impact of remdesivir on SARS-CoV-2 evolution in vivo. JCI Insight. 2025;10(4). doi:10.1172/jci.insight.182376

BibTeX
@article{LingHu2025,
  author = {Ling-Hu, Ted and Simons, Lacy M and Rios-Guzman, Estefany and Carvalho, Alexandre Machado and Agnes, Maria Francesca R and Alisoltanidehkordi, Arghavan and Ozer, Egon A and Lorenzo-Redondo, Ramon and Hultquist, Judd F},
  title = {The impact of remdesivir on SARS-CoV-2 evolution in vivo},
  journal = {JCI Insight},
  year = {2025},
  volume = {10},
  number = {4},
  doi = {10.1172/jci.insight.182376}
}
Kostenlos starten →